Abstract: The present application discloses a method for treating microbial infection using an antimicrobial composition comprises antimicrobial peptide which contains at least one VGFPV motif.
Type:
Application
Filed:
October 7, 2011
Publication date:
April 11, 2013
Applicant:
MOREHOUSE SCHOOL OF MEDICINE
Inventors:
Vincent Craig Bond, Michael Powell, Ming Bo Huang, Syed Ali, Martin Neville Shelton
Abstract: Methods for prevention, treatment or inhibition of the growth or metastasis of cancer cells in a subject are disclosed. One method comprises the step of administering to the subject a therapeutically effective amount of tumor associated antigen binding ligand-coated planetary ball milled (PBM) nanoparticles containing a cytotoxic agent.
Type:
Application
Filed:
August 8, 2012
Publication date:
February 21, 2013
Applicant:
MOREHOUSE SCHOOL OF MEDICINE
Inventors:
James W. Lillard, JR., Shailesh Singh, Rajesh Singh
Abstract: Assays using binding studies involving function of BRCA1a protein have use for diagnosis and for evaluation of possible tumorogenicity of agents, particularly estrogenic agents. The assays do not rely on use of a probe for only specific sequences, but on effects of known and unknown or not previously studied sequences (consequence of genetic changes) or posttranslational modification of BRCA1 proteins (as a consequence of epigenetic changes) as seen in hereditary and sporadic cancers.
Abstract: Biomarkers for predicting the severity of malaria and methods for their detection are disclosed. In one aspect, the present application discloses CXCL4, CXCL10, VEGF, PGDF, IL-1Ra, IL-8, MIP-1?, sFas, Fas-L, sTNF-R2, and sTNF-R1 as biomarkers for the severity of malaria. In another aspect, the present application discloses a method for determining the severity of malaria and predicting mortality due to cerebral malaria. The method comprises the detection of the biomarkers CXCL4 and/or CXCL10 and at least one more biomarker and determining the severity of malaria and predicting mortality due to cerebral malaria based upon the ratio of expression of the biomarkers in the subject versus the expression of the biomarkers in a control.
Type:
Grant
Filed:
December 2, 2010
Date of Patent:
February 5, 2013
Assignee:
Morehouse School of Medicine
Inventors:
Jonathan K. Stiles, James W. Lillard, Henry B. Armatei Armah, Nana Otoo Wilson, Venkatachalam Udhayakumar
Abstract: Biomarkers for predicting the severity of malaria and methods for their detection are disclosed. In one aspect, the present application discloses CXCL4, CXCL10, VEGF, PGDF, IL-1Ra, IL-8, MIP-1?, sFas, Fas-L, sTNF-R2, and sTNF-R1 as biomarkers for the severity of malaria. In another aspect, the present application discloses a method for determining the severity of malaria and predicting mortality due to cerebral malaria. The method comprises the detection of the biomarkers CXCL4 and/or CXCL10 and at least one more biomarker and determining the severity of malaria and predicting mortality due to cerebral malaria based upon the ratio of expression of the biomarkers in the subject versus the expression of the biomarkers in a control.
Type:
Grant
Filed:
May 2, 2012
Date of Patent:
February 5, 2013
Assignee:
Morehouse School of Medicine
Inventors:
Jonathan K. Stiles, James W. Lillard, Henry B. Armatei Armah, Nana Otoo Wilson
Abstract: Novel peptides that inhibit the release of microparticles from cells are disclosed. The peptide contains at least one VGFPV motif at the N-terminal and has a length of 10-100 amino acids. Also disclosed is polynucleotide encoding the peptide, expression vectors carrying the polynucleotide, and methods for treating AIDS and tumors using the novel peptides.
Type:
Application
Filed:
September 17, 2012
Publication date:
January 17, 2013
Applicant:
MOREHOUSE SCHOOL OF MEDICINE
Inventors:
Vincent Craig Bond, Michael Powell, Ming Bo Huang, Syed Ali, Andrea D. Raymond, Martin Neville Shelton, Francois Jean Villinger
Abstract: Novel peptides that inhibit the release of microparticles from cells are disclosed. The peptide contains at least one VGFPV motif at the N-terminal and has a length of 10-100 amino acids. Also disclosed is polynucleotide encoding the peptide, expression vectors carrying the polynucleotide, and methods for treating AIDS and tumors using the novel peptides.
Type:
Application
Filed:
September 17, 2012
Publication date:
January 17, 2013
Applicant:
MOREHOUSE SCHOOL OF MEDICINE
Inventors:
Vincent Craig Bond, Michael Powell, Ming Bo Huang, Syed Ali, Andrea D. Raymond, Martin Neville Shelton, Francois Jean Villinger
Abstract: Biomarkers for predicting the severity of malaria and methods for their detection are disclosed. In one aspect, the present application discloses CXCL4, CXCL10, VEGF, PGDF, IL-1Ra, IL-8, MIP-1?, sFas, Fas-L, sTNF-R2, and sTNF-R1 as biomarkers for the severity of malaria. In another aspect, the present application discloses a method for determining the severity of malaria and predicting mortality due to cerebral malaria. The method comprises the detection of the biomarkers CXCL4 and/or CXCL10 and at least one more biomarker and determining the severity of malaria and predicting mortality due to cerebral malaria based upon the ratio of expression of the biomarkers in the subject versus the expression of the biomarkers in a control.
Type:
Application
Filed:
May 2, 2012
Publication date:
January 10, 2013
Applicant:
MOREHOUSE SCHOOL OF MEDICINE
Inventors:
Jonathan K. STILES, James W. LILLARD, Henry B. Armatei ARMAH, Nana Otoo WILSON
Abstract: It is possible to inhibit inflammatory processes by administration of antibodies to chemokines. Identification of chemokines which are over-produced makes it possible to block specific chemokine activity using antibodies to the over-expressed chemokines.
Type:
Application
Filed:
June 29, 2012
Publication date:
December 13, 2012
Applicant:
MOREHOUSE SCHOOL OF MEDICINE
Inventors:
James W. Lillard, JR., Udai P. Singh, Shailesh Singh, Jonathan K. Stiles
Abstract: This application is directed to chemokine-immunoglobulin fusion polypeptides and chemokine-polymer conjugates. The fusion polypeptides and conjugates can be used for treating chemokine receptor-mediated disorders and modulating inflammation, inflammatory cell motility, cancer cell motility, or cancer cell survival.
Abstract: It is possible to inhibit inflammatory processes by administration of antibodies to chemokines. Identification of chemokines which are over-produced makes it possible to block specific chemokine activity using antibodies to the over-expressed chemokines.
Type:
Grant
Filed:
May 11, 2011
Date of Patent:
November 27, 2012
Assignee:
Morehouse School of Medicine
Inventors:
James W. Lillard, Udai P. Singh, Shailesh Singh, Jonathan K. Stiles
Abstract: Methods for preventing or inhibiting inflammation in a subject are disclosed. In one aspect, the method comprises administering to a subject diagnosed with an inflammatory disease an effective amount of an anti-inflammatory agent that (1) inhibits the expression of CXCL9, CXCL10, CXCL11, CXCL13, CXCR3 and/or CXCR5, or (2) inhibits the interaction between CXCR3 and CXCL9, CXCL10 or CXCL11, or between CXCR5 and CXCL13, or (3) inhibits a biological activity of CXCL9, CXCL10, CXCL11, CXCL13, CXCR3 and/or CXCR5, wherein the agent comprises an antibody, antibody fragment, short interfering RNA (siRNA), aptamer, synbody, binding agent, peptide, aptamer-siRNA chimera, single stranded antisense oligonucleotide, triplex forming oligonucleotide, ribozyme, external guide sequence, or an agent-encoding expression vector.
Abstract: A method for detecting an inflammatory disease in a subject is disclosed. The method comprises the steps of (a) detecting a level of expression of one or more inflammatory disease markers in a biological sample obtained from the subject; and (b) comparing the level of expression of said one or more inflammatory disease markers in the biological sample to a normal level of expression of the one or more inflammatory disease markers, wherein the one or more inflammatory disease markers comprise one or more markers selected from the group consisting of CXCL9, CXCL10, CXCL11, CXCL13, CXCR3 and CXCR5. Also disclosed are a method for monitoring the course of treatment for an inflammatory disease in a subject and a kit for detecting an inflammatory disease in a subject.
Abstract: A method for detecting HIV infection in a mammal is disclosed. The method contains the steps of isolating exosomes from a urine sample of a mammal and detecting the presence of HIV-specific biomarker in said isolated exosomes. A method for diagnosing a mammal with an HIV-associated disease, in particular, HIV-associated nephropathy is also disclosed.
Type:
Application
Filed:
January 11, 2012
Publication date:
August 23, 2012
Applicant:
MOREHOUSE SCHOOL OF MEDICINE
Inventors:
Gale W. Newman, Mike Powell, Akins Doherty, Chamberlain Obialo
Abstract: A method for detecting HIV infection in a mammal is disclosed. The method contains the steps of isolating exosomes from a urine sample of a mammal and detecting the presence of HIV-specific biomarker in said isolated exosomes. A method for diagnosing a mammal with an HIV-associated disease, in particular, HIV-associated nephropathy is also disclosed.
Type:
Application
Filed:
January 11, 2012
Publication date:
August 16, 2012
Applicant:
MOREHOUSE SCHOOL OF MEDICINE
Inventors:
Gale W. Newman, Mike Powell, Akins Doherty, Chamberlain Obialo
Abstract: A method for molecular haplotyping of a subject is disclosed. The method comprises: randomly selecting a set of chromosomes in each of a plurality of lyzed diploid cells of the subject, collecting the selected chromosomes from said plurality of cells into a plurality of sample tubes, wherein each sample tube contains chromosomes selected from one or more cells, genotyping genomic DNA in each sample tube, and determining haplotype of the alleles based on allele nucleotide sequence information and corresponding nucleotide signal intensities from genotyping data. Other methods for molecular haplotyping using single cell lysate or single cell microdissection are also disclosed.
Abstract: Milled nanoparticles comprising a biologically active agent, at least one biopolymer and a coating containing at least one coating which is a polymer or ligand.
Type:
Grant
Filed:
March 20, 2007
Date of Patent:
July 31, 2012
Assignee:
Morehouse School of Medicine
Inventors:
James W. Lillard, Rajesh Singh, Shailesh Singh
Abstract: In one aspect, the present invention relates to a computerized system programmed for providing care support to at least one patient having at least one chronic illness. In one embodiment, the system includes a medical professional module adapted for receiving, storing, and providing data in communication with at least one medical professional at the point of care, a health coach module adapted for receiving, storing, and providing data in communication with the at least one patient and at least one health coach, a patient module adapted for receiving, storing, and providing data in communication with the at least one patient, and, a public health module adapted for receiving, storing, and providing data in communication with at least one research professional.
Type:
Grant
Filed:
July 14, 2009
Date of Patent:
July 31, 2012
Assignee:
Morehouse School of Medicine
Inventors:
Elizabeth Ofili, Priscilla I. Pemu, Alexander Quarshie, Priscilla Johnson, Laura J. Linn, Dipendra Kaur, Jacquelyn Ali
Abstract: A method for the isolation, storage and retrieval of mature retinal cells is disclosed. The Method is applicable to adult mammalian cone cells, and more particularly human cone cells, and to healthy as well as pathological or otherwise altered cone cells. A kit for the isolation, storage and retrieval of mature retinal cells is also described.